How to be Smarter than the Guidelines

G. Michael Allan



Shining Evidence on Guidelines & Performance Measures



Faculty/Presenter Disclosure

- Faculty/Presenter: G. Michael Allan
- Relationships with commercial interests:
 - Grants/Research Support: Not applicable
 - Speakers Bureau/Honoraria: Not applicable
 - **Consulting Fees:** Not applicable
 - Other:
 - Employed by University of Alberta, Alberta Health
 - Non-profit sources including Alberta College of Family Physicians, TOP, IHE, CADTH, etc.

Faculty/Presenter Disclosure

- I have Chaired, Co-Chaired & Participated in guidelines on
 - Lipids
 - Diabetes
 - Cancer (Prostate)
 - Osteoporosis
 - Rheumatoid Arthritis

Objectives and Plan

- Review the strengths of guidelines
- Discuss the Limitations of Guidelines
- Issues in applying guidelines in practice
- Some examples where guidelines are not linked to best evidence

 The Goal: Worry less about taking care of guidelines (+ performance measures) and more about people



Guidelines: Answers for Uncertainty

- 3 "uncertainties" for every 2 patient encounters¹
- Searching (30-60 minutes²) & appraising a paper
 - -30 patients =45 questions
 - >60 hours/day
- In truth, Doctors³
 - Spend 2 minutes getting answers to their questions
 - Search pubmed for <1% of their question
 - Do critical appraisals < 0.1% of their questions

 Ann Intern Med 1991; 114:576-81. J Fam Pract. 1992;35:265-9.
 J Fam Pract. 1996; 43:140-4. Bull Med Libr Assoc 1994; 82: 140-146
 BMJ 1999; 319: 358-61.

Guidelines: What else they offer

- Help us keep up-to-date
- Alternatively: We *need* to read 7,287 articles per month relevant to primary care
 - That means: 21 hours of reading every day¹
- Guidelines also provide suggestions on issues lacking clear evidence.

Confusing Messages



Clinical practice guideline on diagnosis and treatment of hyponatraemia

the AGREEII tool - scope and purpose, stakeholder nt, clarity of presenlependence - and the designed to provide information and assist in decisionhe different guidance ctory (2). making related to this topic. It was not intended to define ort clinical decision a standard of care and should not be construed as one. isional dealing with mers, internists, sur with hyponatraemia It should not be interpreted as prescribing an exclusive nospital setting. The cymakers for inform orting the decision course of management.

Innshruck Austria

This guideline was developed as a joint venture

Hospital, Belgium

Sabine van der Veer Implementation Specialist, Amsterdam Medical Centre, Amsterdam. The Netherlands

Consultant Intensivist, Innsbruck University Hospital,

and what the guideline developers considered. The scope was determined at a first meeting held in Barcelona in October 2010 with representatives of ESICM, ESE and ERBP present.

170:3

high-quality guidelines in this field (1). The guidance

documents scored low to moderate in the six domains of

G3

geons and other physicians dealing with hyponatraemia 3. Purpose and scope of this in both an outpatient and an in-hospital setting. The 3.1. Why was this guideline produ The purpose of this Clinical Pract guideline was also developed for policymakers for informprovide guidance on the diagnost adult individuals with hypotonic h designed to provide information a ing standards of care and for supporting the decisionmaking related to this topic. It was r a standard of care and should not It should not be interpreted as pre making process. course of management.

www.eje-online.org


ine intended to cover

This guideline was developed of three societies representing spec interest in hyponatraemia: the ESI ERA-EDTA, represented by ERBP.

All three societies agreed that there was a need for guidance on diagnostic assessment and therapeutic management of hyponatraemia. A recent systematic review, which included three clinical practice guidelines diagnosis or treatment of the underlying conditions that can and five consensus statements, confirmed the lack of be associated with hypotonic hyponatraemia.

diagnosis and management of both acute and chronic hypotonic hyponatraemia in case of reduced, normal and increased extracellular fluid volume. It does not cover the

н, нуров



Prostate cancer screening: Canadian guidelines 2011

"However, the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that a DRE did not provide any additive information beyond PSA. **(Level 1 Evidence.)**" p236

Final Recommendation "Initial screening should include DRE and PSA." p239

How consistent are guidelines?

- There is disagreement between Task Forces¹
- Guidelines don't seem to agree
- Example, in COPD, even the Diagnosis Debated.

	FEV; Predicted of Normal Value (%)				
Classification of disease severity	ATS ³	BTS7	ERS ⁹	GOLD ¹⁰	
Stage I (mild)	≥ 50	60-79	≥70	≥ 80	
Stage II (moderate)	35-49	40-59	50-69	30-80	
Stage III (severe)	< 35	< 40	< 50	< 30	

TABLE 2–3 Staging Chronic Obstructive Pulmonary Disease for Disease Severity*

*In all patients with a reduced FEV1/FVC ratio, usually less than 70%, which is the mark of obstructive ventilatory impairment.

FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; ATS = American Thoracic Society; BTS = British Thoracic Society; ERS = European Respiratory Society; GOLD = Global Initiative for Chronic Obstructive Lung Disease. 1995 - 2001

1. Can Fam Physician 2006;52:58-63.

<u>Why do "Evidence based"</u> <u>Guidelines Vary</u>

- What is Evidence?
- Remember: expert opinion is still considered evidence.

Commentary

Laws are like sausages; it is better Peripheral Arterial Disease Practice (and Sausage not to see them being made.

Otto Von Bismarck

David Sacks, MD, and Ziv J. Haskal, MD

J Vasc Interv Radiol 2006; 17:1379-1381

Abbreviations: PAD = peripheral arterial disease, RAS = renal artery st

Laws are like sausages; it is better not to see them being made. -Otto Von Bismarck

When you assemble a number of men to have the advantage of their joint wisdom, you inevitably assemble with those men all their prejudices, their passions, their errors of opinion, their local interests, and their selfish views. From such an assembly can a perfect production be expected? It therefore astonishes me, sir, to find this system approaching so near to perfection as it does.

-Benjamin Franklin on the writing of the United States Constitution

AFTER 4 years of work, the multispecialty clinical practice guidelines for the diagnosis and treatment of patients with peripheral arterial disease (PAD) have been completed and released (1). The document was created under the auspices of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, with three writing committee chairs with backgrounds in cardiology and vascular medicine

Neither of the authors has identified a conflict of interest

© SIR. 2006

DOI: 10.1097/01.RVI.0000235701.48178.66

radiology (Ziv J. Haskal, MD), and vascular surgery (Norman Hertzer, MD). Writing committee members included representatives from the fields of interventional radiology, vascular medicine, cardiology, vascular surgery, and nephrology. The 191-page final document will, amazingly, be condensed not only into an executive summary of approximately 60 pages, but also into a pocket guide of recomdations and a downloadable verandheld PCs. sions

(Alan T. Hirsch, MD), interventional

The intens idience for this dococialist and ument is the vascu the primary care physician, the attending level to the resident in tra-

ing, and the document will be of use to interventional radiologists who pro-such as vide clinical care to patients with PAD. reasona The intention of the document is to ness is significantly improve the quality of or not w care provided to patients with PAD. strong (class II Recommendations are made to provide diagnostic testing for targeted "should ed/indi "at-risk" populations with measurement of the ankle-brachial index. Even recomm asymptomatic patients with PAD are weak le known to be at high risk of significant cur whe morbidity and mortality from diffuse that an atherosclerosis, and the detection of times, n PAD in such patients will lead to recethically ommendations for further targeted random therapies to reduce their cardiovascudations lar risk. Inasmuch as PAD is indeed a common common high-risk cardiovascular illness, one can easily anticipate that the recommendations for risk factor modification (ie, the use of statins, antihypertensive agents, angiotensin-converting enzyme inhibitors, antiplatelet medications, and smoking cessation

interventions) could become part of a "pay-for-performance" program for the care of patients receiving vascular treatments (2).

All consensus documents by necessity combine an evaluation of true "evidence," as derived from peer-re-

ed,"

viewed, When you assemble a number of "expert serve of mendati made 1 men to have the advantage of their linked t (Table). tions (cl joint wisdom, you inevitably tion ver should dati assemble with those men all their prejudices, their passions, their errors of opinion, their local interests, and their selfish views. Benjamin Franklin

critical limb ischemia should undergo expedited evaluation and treatment of factors that are known to increase the risk of amputation" (section 2.4.3 [1]). Such recommendations may seem so obvious as not to merit inclusion, but what is obvious to a specialist may

J Vasc Interv Radiol. 2006;17(9):1379-81.

From the Department of Radiology (D.S.), The Reading Hospital and Medical Center, West Reading, Pennsylvania; and Division of Vascular and Interventional Radiology (Z.J.H.), New York Presbyterian Hospital/Columbia University, New York, New York. Address correspondence to D.S.; E-mail: davidsacks@pol.net

Hierarchy of Evidence

Systematic Reviews

Randomized Controlled Trials

Cohort Studies

Case-Control Studies

Case Series, Case Reports

Editorials, Expert Opinion

"Evidence based" Guidelines

Level of Evidence	Cardiology ¹	Infectious Disease ²
Level 1		
Level 2		
Level 3		
the state the	A	dam The hard the hard

"Evidence based" Guidelines

Level of Evidence	Cardiology ¹	Infectious Disease ²
Level 1	11%	14%
Level 2		
Level 3		

1. JAMA. 2009;301(8):831-841. Arch Intern Med. 2011;171(1):18-22

"Evidence based" Guidelines

Level of Evidence	Cardiology ¹	Infectious Disease ²
Level 1	11%	14%
Level 2	41%	31%
Level 3	48%	55%

Additionally: ~20% of recommendations are out-of-date at 3-6 yrs.

This is ~3x more common in lower levels of evidence.

JAMA. 2009;301(8):831-841. 2 Arch Intern Med. 2011;171(1):18-22
 Garcia LM. CMAJ 2014. DOI:10.1503 /cmaj.140547. JAMA 2014;311:2092-100.

Depending on Experts



<u>Who is writing Primary Care</u> <u>Guidelines?</u>

- 190 primary care CPG with 2539 authors
 - 53% were specialists, 17% family doctors
 - 8% Non-clinicians, 5% nurses, 3% pharmacists
 - Rest: Other (NP, physio, unknown, etc)
- Specialists were more
 - $> \frac{3}{4}$ of the doctors $\& > \frac{1}{2}$ of everyone!

Can Fam Physician. 2015 Jan;61(1):52-8.

So do Experts do a better job reviewing the evidence?

- "Our data suggest that <u>experts</u>, on average, write reviews of inferior quality;
 - that the greater the expertise the more likely the quality is to be poor;
 - and that the poor quality may be related to the strength of their prior opinions; " (Oxman & Guyatt, 1993)

It can be confusing,...

- Editorial: "Treating to New Targets": plea for a LDL cholesterol target of or below 2 in any patient with coronary heart disease"
- What TNT asked: With CVD and LDL <3.4 is 80 mg better than 10 mg (Atorvastatin).

Proper: A plea for High Dose Statin in CVD patients regardless of cholesterol.

Rev Med Liege. 2005 Apr;60(4):264-7. N Engl J Med. 2005 Apr 7;352(14):1425-35.

Another Reason Interpretation Varies

- Conflict of Interest: 14 CPG, 288 "authors"
- Of those that could report COI (211);
 - -65% reported COI
 - 35% reported no COI
 - 11% of them had a COI (reported within last 2 yrs)

Canada: 69% of CPG don't include COI
 – COI: specialist 49%, FD 28%, Pharmacists 30%

BMJ 2011;343:d5621 doi: 10.1136/bmj.d5621. Can Fam Physician. 2015;61(1):52-8


CMAJ

COMMENTARY

Guidelines are too important to be left to clinical experts

- The main authors of Primary Care Guidelines are specialists
- And they generally do a poorer job reviewing evidence without bias?

Specialist vs Generalist



Applying Tertiary Research to a General Population

- Significant difference between primary care (most patients seen) & specialty care (most research)¹
- Tertiary care research often exaggerates benefit
- 1) Treatment of Depression²
 - Tertiary care = 53% response or better
 - Primary care = 39% response
- 2) Weight loss with Orlistat 1yr (120mg TID)³
 - Tertiary care = 22% lost 5% weight
 - Primary care = 13% lost 5% weight

1) Evid. Based Med 2008;13;132-3. 2) CMAJ 2008;178:296-305. Am J Psychiatry 2009; 166:599–607 3) JAMA 1999;281:235-42. J Int Med 2000;248:245-54

Many other studies done WITHIN countries, both industrial and developing, show that areas with better primary care have better health outcomes, including total mortality rates, heart disease mortality rates, and infant mortality, and earlier detection of cancers such as colorectal cancer, breast cancer, uterine/cervical cancer, and melanoma. The opposite is the case for higher specialist supply, which is associated with worse outcomes.

Thanks Barb Starfield.

Many other studies done WITHIN countries, both industrial and developing, show that areas with better primary care have better health outcomes, including total mortality rates, heart disease mortality rates, and infant mortality, and earlier detection of cancers such as colorectal cancer, breast cancer, uterine/cervical cancer, and melanoma. The opposite is the case for higher specialist supply, which is associated with worse outcomes.

Thanks Barb Starfield.

Many other studies done WITHIN countries, both industrial and developing, show that areas with better primary care have better health outcomes, including total mortality rates, heart disease mortality rates, and infant mortality, and earlier detection of cancers such as colorectal cancer, breast cancer, uterine/cervical cancer, and melanoma. The opposite is the case for higher specialist supply, which is associated with worse outcomes. Thanks Barb Starfield.

There is even a formula,...

- "An increase of 1 primary care physician per 10,000 persons was associated with a reduction of 3.5 deaths per 10,000.
- An increase of 1 specialty physician per 10,000 population was associated with approximately 1.5 additional deaths per 10,000."

Target Shooting



How are "we" doing?

- Primary Care Clinicians are not hitting the guideline targets.
- DM in the US,
 - 93% DM pts did not hit all targets.
- CAD patients
 - 84% not at targets
- Cholesterol Targets in Canada,
 - 76% not at LDL targets

Can Fam Physician. 2014;60:541.JAMA 2004;291:335-42. J Manag Care Pharm. 2006;12;745-51

Do the RCT's hit Targets?


- <u>Small</u> RCT to hit targets in BP, Chol & sugar¹
 - 80 patients: only 1 hit all targets
- From 3 target based RCTs of Diabetics³
 - 77% did not hit targets for 4 outcomes.
- Review: CVD pts, highest dose of statins²
 - <50% actual get an LDL < 2 mmol/L.</p>
 - Outcomes improved in both, despite not hitting targets

1) N Engl J Med 2003;348:383-93. N Engl J Med 2008;358:580-91. 2) CMAJ 2008;178(5):576-84. 3) Can Fam Physician. 2014 Jun;60(6):541.

You can't be too rich or too low: Targets

- Blood Glucose:
 - 2004: A1c \leq 7% (& \leq 6% "in whom it can be safely achieved")
 - Now: A1c ≤7% (& 7.1-8.5% for many)
- Lipids: LDL:
 - − Old: LDL \leq 2mmol/L in high risk or \leq 3.5mmol/L in moderate.
 - New: No LDL target level.
- Blood pressure:
 - Old: 140/90 & 130 if Diabetic or renal disease
 - New: age ≥60 150/90, all others 140/90
- Rate Control:
 - Old: <80 Heart Rate, New <110 (<100)</p>

You can't be too rich or too low: How many J-curves are enough?







Is there time for Chronic Disease

	Total	No. (%) of Cases		Number of Visits		Minutes	Hours
Disease	Cases	Uncontrolled	Controlled	Uncontrolled	Controlled		Per Year
Hyperlipidemia	511	417 (81.6)	94 (18.4)	8	2	10	587
Hypertension	472	312 (66)	160 (34)	12	2	10	704
Depression	118	58 (49)	60 (51)	12	4	10	156
Asthma	183	62 (33.6)	121 (66.3)	4	2	10	82
Diabetes	145	91 (63)	54 (37)	4	2	10	79
Total hours per year							1,581
Total hours per work day							6.7

 For 10 conditions if not well controlled up to 10.6 hours/day.¹

Physicians also need 7.4 hrs/day for preventive services²

1) Ann Fam Med 2005;3:209-214. 2) Am J Public Health. 2003;93(4):635-41.

Table 3. Treatment Regimen Based on Clinical Practice Guidelines for a Hypothetical 79-Year-Old Woman With Hypertension, Diabetes Mellitus, Osteoporosis, Osteoarthritis, and COPD*

Time	Medications†	Other
7:00 AM	Ipratropium metered dose inhaler 70 mg/wk of alendronate	Check feet Sit upright for 30 min on day when alendronate is taken Check blood sugar
8:00 AM	500 mg of calcium and 200 IU of vitamin D 12.5 mg of hydrochlorothiazide 40 mg of lisinopril 10 mg of glyburide 81 mg of aspirin 850 mg of metformin 250 mg of naproxen 20 mg of omeprazole	Eat breakfast 2.4 g/d of sodium 90 mmol/d of potassium Low intake of dietary saturated fat and cholesterol Adequate intake of magnesium and calcium Medical nutrition therapy for diabetes‡ DASH‡
12:00 рм		Eat lunch 2.4 g/d of sodium 90 mmol/d of potassium Low intake of dietary saturated fat and cholesterol Adequate intake of magnesium and calcium Medical nutrition therapy for diabetes‡ DASH‡
1:00 PM	Ipratropium metered dose inhaler 500 mg of calcium and 200 IU of vitamin D	
7:00 РМ	Ipratropium metered dose inhaler 850 mg of metformin 500 mg of calcium and 200 IU of vitamin D 40 mg of lovastatin 250 mg of naproxen	Eat dinner 2.4 g/d of sodium 90 mmol/d of potassium Low intake of dietary saturated fat and cholesterol Adequate intake of magnesium and calcium Medical nutrition therapy for diabetes‡ DASH‡
11:00 РМ	Ipratropium metered dose inhaler	
As needed	Albuterol metered dose inhaler	

Treatment for a Hypothetical 79-Year-Old Woman With Hypertension, Diabetes Mellitus, Osteoporosis, Osteoarthritis, and COPD

Abbreviations: ADA, American Diabetes Association; COPD, chronic obstructive pulmonary disease; DASH, Dietary Approaches to Stop Hypertension.

*Clinical practice guidelines used: (1) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure VII.³⁸ (2) ADA¹⁹⁻³²; glycemic control is recommended; however, specific medicines are not described. (3) American College of Rheumatology³³⁻³⁶; recent evidence about the safety and appropriateness of cyclooxygenase inhibitors, particularly in individuals with comorbid cardiovascular disease, led us to omit them from JAMA 2005;294:716-724.

Some things just don't make sense?



Quality of Life Comparison

Outcome	QOL Utilities
Mild Stroke	0.70
Angina	0.64
Diabetic Neuropathy	0.66

Comprehensive Diabetic Care

0.64

Diabetes Care 2007;30:2478-83

Applying Guidelines to patients

- A study found that guidelines rarely included a discussion of patient-centered or shared informed decision making.
 - Of 5 large Canadian guidelines ≈ 0.1% content

Side Effects: What Patients think when we say it's Uncommon?

Lancet 2002; 359: 853-54

Description	EU Assigned Meaning
Very Common	>10%
Common	1-10%
Uncommon	0.1-1%
Rare	0.01 – 0.1%
Very Rare	<0.01%

Side Effects: What Patients think when we say it's Uncommon?

Description	EU Assigned Meaning	Patients Perceived Chance
Very Common	>10%	65%
Common	1-10%	45%
Uncommon	0.1-1%	18%
Rare	0.01 – 0.1%	8%
Very Rare	<0.01%	2%

Patients over estimated risk by 5 to 200 times.

Lancet 2002; 359: 853-54



Performance Measures Myths

- "Unintended" consequences are unpredictable
- False: Many (eg patient de-enrolment) predictable¹
- Exceptions will be over-used:
- False: 94% of exceptions are appropriate²
- More incentive = better performance
 False: Those with <10% pay from incentive³

1) Ann Fam Med 2009;7:121-127. 2) Ann Intern Med. 2010 Feb 16;152(4):225-31. 3) J Gen Intern Med



		Cancer Screening
		Mammogram NNS 377- 2000 x 10 yrs
		FIT (FOB) NNS 1200 x 10 yrs
		PSA: NNS 441- 1410 x 10 yrs

	CVD (primary prevention)	Cancer Screening
	Statin: NNT 77- 55 over 5 years	Mammogram NNS 377- 2000 x 10 yrs
	Metformin in DM: NNT 29 over 5 years (MI only)	FIT (FOB) NNS 1200 x 10 yrs
	ASA: NNT 346- 427 over 5 years.	PSA: NNS 441- 1410 x 10 yrs

	Long-term/Prevent Symptoms	CVD (primary prevention)	Cancer Screening
	Antidepressants: Depression NNT 7-9 in 6 wks response	Statin: NNT 77- 55 over 5 years	Mammogram NNS 377- 2000 x 10 yrs
	Constipation (chronic): PEG, NNT 2-3 for 6 months.	Metformin in DM: NNT 29 over 5 years (MI only)	FIT (FOB) NNS 1200 x 10 yrs
	Headache: TCA or Beta-blocker, NNT 4-8 x6 months reduce 50%	ASA: NNT 346- 427 over 5 years.	PSA: NNS 441- 1410 x 10 yrs

Treating Symptoms	Long-term/Prevent Symptoms	CVD (primary prevention)	Cancer Screening
AOM: Amoxil NNT 3- 10 in 4-10 days Sx free	Antidepressants: Depression NNT 7-9 in 6 wks response	Statin: NNT 77- 55 over 5 years	Mammogram NNS 377- 2000 x 10 yrs
Headache: ASA - sumatriptan, NNT 5- 9 pain free 2 hrs	Constipation (chronic): PEG, NNT 2-3 for 6 months.	Metformin in DM: NNT 29 over 5 years (MI only)	FIT (FOB) NNS 1200 x 10 yrs
OA Knee: steroid shot, NNT 3-5 global improve x1 wks	Headache: TCA or Beta-blocker, NNT 4-8 x6 months reduce 50%	ASA: NNT 346- 427 over 5 years.	PSA: NNS 441- 1410 x 10 yrs

	Treating Symptoms	Long-term/Prevent Symptoms	CVD (primary prevention)	Cancer Screening
	AOM: Amoxil NNT 3- 10 in 4-10 days Sx free	Antidepressants: Depression NNT 7-9 in 6 wks response	Statin: NNT 77- 55 over 5 years	Mammogram NNS 377- 2000 x 10 yrs
	Headache: ASA - sumatriptan, NNT 5- 9 pain free 2 hrs	Constipation (chronic): PEG, NNT 2-3 for 6 months.	Metformin in DM: NNT 29 over 5 years (MI only)	FIT (FOB) NNS 1200 x 10 yrs
	OA Knee: steroid shot, NNT 3-5 global improve x1 wks	Headache: TCA or Beta-blocker, NNT 4-8 x6 months reduce 50%	ASA: NNT 346- 427 over 5 years.	PSA: NNS 441- 1410 x 10 yrs
Patient Years	~1 benefit for every month	1 benefits for every 1-4 years	1 benefits every ~150-2000 yrs	1 benefits every ~10,000 years

Sometimes, The answers are hard

City unsure why the sewer smells

By KRISTIN HAY H-P Correspondent

SOUTH HAVEN — The tests have been inconclusive in trying to locate the source of a mysterious odor that has been detected in several downtown South Haven businesses.

Bob Stickland, the director of the city's Board of Public Works, old the City Council in a workStickland said he will discuss the strategy of putting a non-toxic smoke into the sewer to detect the path of the offensive gas emanating from basement drains.

"Somebody is putting something into the sewer that is creating the odor," Stickland said in an interview after the council meeting. "We are trying to find out what it is."

Heavy industries pre-treat waste

The future

<u>Guidelines</u> should

- 1. Increase primary care involvement,
- 2. Be transparent with conflict of interest,
- 3. Interpretation of evidence and
- 4. State they augment decision-making, not direct it

• Performance measure, if present, should

- Stop focusing on what can be measured (numbers) and more on,
- 2. What should be measured

Be suspicious,...

motorist was not found.

10:10 p.m.: <u>Suspicious people</u> were reportedly doing something with flashlights by the side of North 5th Street in Custer. <u>A deputy</u> checked and found the people were not suspicious, but merely <u>Canadian</u>. The out-of-towners were enjoying an evening stroll.

